De Backer O, Dangas GD, Jilaihawi H, et al. - In this substudy of a large randomized trial, experts randomized 231 people who underwent successful transcatheter aortic valve replacement (TAVR) and who did not have an indication for long-term anticoagulation to a rivaroxaban-based antithrombotic strategy or an antiplatelet-based strategy in order to determine whether anticoagulation could decrease subclinical leaflet thickening and leaflet motion following TAVR. It was discovered that in preventing subclinical leaflet-motion abnormalities, compared with an antiplatelet-based strategy, the rivaroxaban-based antithrombotic approach was more efficient. Nonetheless, in the main trial, compared with the antiplatelet-based strategy, the rivaroxaban-based strategy was related to a greater risk of death or thromboembolic complications and bleeding.